Kenvue Inc. (KVUE) to Issue Quarterly Dividend of $0.21 on October 2nd

Posted by on Sep 19th, 2026

Kenvue Inc. (NYSE:KVUE – Get Free Report) announced a quarterly dividend on Thursday, September 10th. Investors of record on Monday, September 21st will be given a dividend of 0.21 per share on Friday, October 2nd. This represents a c) annualized dividend and a yield of 4.7%. The ex-dividend date of this dividend is Monday, September 21st.

Kenvue has a dividend payout ratio of 68.9% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Kenvue to earn $1.23 per share next year, which means the company should continue to be able to cover its $0.84 annual dividend with an expected future payout ratio of 68.3%.

Kenvue Stock Performance

Shares of Kenvue stock opened at $17.82 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.01 and a quick ratio of 0.71. The firm has a market capitalization of $34.22 billion, a P/E ratio of 20.48, a P/E/G ratio of 1.64 and a beta of 0.46. Kenvue has a fifty-two week low of $14.02 and a fifty-two week high of $20.13. The company’s 50 day moving average price is $18.89 and its two-hundred day moving average price is $18.20.

Kenvue (NYSE:KVUE – Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported $0.31 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.01). The business had revenue of $3.96 billion for the quarter, compared to analyst estimates of $3.97 billion. Kenvue had a return on equity of 21.22% and a net margin of 10.76%.The firm’s quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.29 earnings per share. On average, equities analysts forecast that Kenvue will post 1.14 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Barclays upped their price target on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 21st. UBS Group lowered their price objective on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research report on Tuesday, August 11th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kenvue in a research note on Friday, September 11th. Wall Street Zen cut Kenvue from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Zacks Research downgraded shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Three equities research analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $19.27.

View Our Latest Stock Analysis on Kenvue

About Kenvue

(Get Free Report)

Kenvue Inc is a global consumer health company that develops, markets and sells products designed to support everyday health and personal care. Its portfolio spans over-the-counter medicines, skin health and beauty, essential health products, and baby and family care.

The company’s brands include Tylenol, Motrin, Zyrtec and Benadryl in self-care; Neutrogena, Aveeno and Clean & Clear in skin health and beauty; Listerine in oral care; and Johnson’s and Band-Aid in baby care and essential health.

Read More

Dividend History for Kenvue (NYSE:KVUE)

Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.